Antimicrobial resistance: Concerns of healthcare providers and people with CF

  18 June 2020

Chronic lung infections and their treatment pose risks for the development of antimicrobial resistance (AMR) in people with cystic fibrosis (PWCF). In this study, we evaluated the attitudes of healthcare providers’ (HCP) and PWCF or their parents’ toward AMR within the international CF community.

These results highlight that AMR is relevant to CF HCP and PWCF internationally, indicating that educational tools and research are warranted.

Author(s): Wendy Bullington, Sarah Hempstead, Alan R. Smyth, Pavel Drevinek, Lisa Saiman, Valerie J. Waters, Scott C. Bell, Donald R. Van Devanter, Patrick A. Flume, Stuart Elborn, Marianne S Muhlebach
Healthy Patients  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Your Biweekly Source for Global AMR Insights!

Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.

Don’t miss out on staying ahead in the global AMR movement—subscribe now!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed